Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006632003
Mon, 14.11.2022
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
Planegg/Munich, Germany, November 14, 2022
Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
GRADUATE studies did not meet primary endpoint
MorphoSys [ … ]
Thu, 10.11.2022
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, November 10, 2022
Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the third quarter and first nine months 2022 results on November 16, 2022 at 10:00 pm CET (9:00 pm GMT [ … ]
Thu, 10.11.2022
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, November 10, 2022
Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the third quarter and first nine months 2022 results on November 16, 2022 at 10:00 pm CET (9:00 pm GMT [ … ]
Thu, 03.11.2022
MorphoSys AG
BOSTON, Mass., USA, November 3, 2022
MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
Presentations – including four oral sessions – feature data supporting the potential benefit of first-line therapy for pelabresib in myelofibrosis and tafasitamab i [ … ]
Thu, 03.11.2022
MorphoSys AG
BOSTON, Mass., USA, November 3, 2022
MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
Presentations – including four oral sessions – feature data supporting the potential benefit of first-line therapy for pelabresib in myelofibrosis and tafasitamab i [ … ]
Thu, 27.10.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, October 27, 2022
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
The findings, including encouraging preliminary efficacy data in various tumor types, were presented during the 34th EORTC-NCI-AAC [ … ]
Thu, 27.10.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, October 27, 2022
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
The findings, including encouraging preliminary efficacy data in various tumor types, were presented during the 34th EORTC-NCI-AAC [ … ]
Thu, 27.10.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, October 27, 2022
GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner, GSK plc (LSE/NYSE: GSK), provided an update on the ContRAst phase III [ … ]
Thu, 27.10.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, October 27, 2022
GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner, GSK plc (LSE/NYSE: GSK), provided an update on the ContRAst phase III [ … ]
Fri, 21.10.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, October 21, 2022
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million)
Anticipated full year 2022 Monjuvi U.S. net product sales of approximately US$ 90 million
Morpho [ … ]